Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

USB Piper Downgrades Genzyme


USB Piper Jaffray downgrades Genzyme (GENZ) shares to market perform from outperform.

Analyst Mark Augustine says after a strong stock performance in 2000-2001, he sees 2002 as a more challenging year. Although he continues to expect strong Renagel sales growth, he believes the peak sales potential lies closer to $500 million than the $1 billion forecast offered by the company.

He views Vevesca's U.S. approval prospects as a coin toss at best. An early take on the company's Fabrazyme competitive situation in Europe is that market share favors TBIO's Replagal, which could put assumptions in Genzyme's EPS at risk.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus